Re-Vana Therapeutics
Manufacturing · United Kingdom · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Mcclay Research Centre 97 Lisburn Rd, Be...Phone Number
+44 2890975814Website
www.revanatx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Re-Vana Therapeutics
Re-Vana Therapeutics is focused on developing sustained release ocular biologics to alleviate the treatment burden of frequent intravitreal injections for patients with sight-threatening diseases. Their innovative technologies include biodegradable, preformed implants like EyeLief and in situ forming implants like OcuLief, designed to deliver a variety of therapeutic modalities. The company aims to improve patient care by providing controlled, sustained release of biologics, peptides, and other molecules over extended periods. Re-Vana collaborates with leading global pharmaceutical companies to advance their preformulation and preclinical studies.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Re-Vana Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Re-Vana Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Re-Vana Therapeutics
Click to see if Re-Vana Therapeutics had a recent Job posting/layoffs
Check if Re-Vana Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Re-Vana Therapeutics recently announced quarterly report
Re-Vana Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Re-Vana Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Re-Vana Therapeutics launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Re-Vana Therapeutics
Compare insights from companies similar to Re-Vana Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Re-Vana Therapeutics
<$5M
1-10
Private
$15.2M
2016
N/A
Company Profile Activity
Activity Insights
Re-Vana Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Re-Vana Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Re-Vana Therapeutics.
Re-Vana Therapeutics financials insights
Gather financial insights about Re-Vana Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Other Financing Round
$3.3M
2022
Series A
$11.9M
Re-Vana Therapeutics Tech Stack
A closer look at the technologies used by Re-Vana Therapeutics
Re-Vana Therapeutics News & Media
Boehringer partners with Re-Vana on extended-release ophthalmic therapeutics
Collaboration involves photo-crosslinked, biodegradable implants designed to enable continuous, 3-to-12-month drug delivery to treat retinal diseases.Boehringer Links with Irish Drug Delivery Start-Up Re-Vana in $1B+ Eye Deal - BioSpace
The German giant is looking to develop new drugs for undisclosed eye diseases using Re-Vana’s extended-release injectable platform to supply drugs to the eye for months at a time.Boehringer Ingelheim and Re-Vana Therapeutics Announce Strategic Collaboration to Develop Long-Acting Ophthalmic Therapies
Boehringer and Re-Vana enter strategic collaboration to develop extended-release eye therapies, aiming to reduce injections and improve patient outcomes.RE-VANA THERAPEUTICS RAISES $11.9 MILLION IN SERIES A FINANCING
Visionary Ventures Leads Financing Round to Support the Development of Sustained Release Ophthalmic Therapeutics BELFAST, Northern Ireland, Nov. 30, 2022 /PRNewswire/ -- Re-Vana Therapeutics Ltd, a privately-held specialty drug delivery company developing sustained-release therapeutics...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Re-Vana Therapeutics
Sign Up For FreeTo access detailed company insights
Re-Vana Therapeutics is focused on developing sustained release ocular biologics to alleviate the treatment burden of frequent intravitreal injections for patients with sight-threatening diseases. Their innovative technologies include biodegradable, preformed implants like EyeLief and in situ forming implants like OcuLief, designed to deliver a var... Read More
